Evidence map›Paper›PMID 40507861›Full record

ArticleInternational journal of molecular sciences2025

Anna Bircher, Egle Katkeviciute, Yasser Morsy, Silvia Lang, Ana Montalban-Arques, Michael Scharl

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anna BircherDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Egle KatkeviciuteDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Yasser MorsyDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.ORCID 0000-0001-8234-1877
Silvia LangDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.ORCID 0000-0002-1216-899X
Ana Montalban-ArquesDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.ORCID 0000-0003-4700-4263
Michael ScharlDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.

Funding

Fondazione San Salvatore NAHolcim Foundation NASwiss Cancer Research Foundation KFS-5372-08-2021-R
6 · The paper itself

Abstract

In recent years, the gut microbiome has been recognized as one influential factor in cancer development. Particularly in colorectal cancer (CRC), several studies observed a major imbalance of the intestinal microbiota, marked by a reduction in beneficial bacterial species, such as

Indexed as

EubacterialesMacrophage ActivationMacrophagesAnimalsCell Line, TumorCoculture TechniquesColorectal NeoplasmsCytokinesGastrointestinal MicrobiomeHumansMiceCytokinescolorectal cancermacrophage polarizationmicrobiotaPeptostreptococcus stomatisRoseburia intestinalis

Identifiers

PMID40507861
PMCPMC12155563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.